Released : October 16, 2017 07:00 RNS Number : 6267T MaxCyte, Inc. 16 October 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Declaration of Audit Remuneration Maryland, USA - 16 October 2017: MaxCyte (LSE: MXCT, MXCR), in order to assist investors in considering the resolutions
Released : October 05, 2017 18:32 RNS Number : 8773S MaxCyte, Inc. 05 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : October 05, 2017 18:31 RNS Number : 8770S MaxCyte, Inc. 05 October 2017 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : September 28, 2017 17:15 RNS Number : 1589S MaxCyte, Inc. 28 September 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Notification of Annual General Meeting Maryland, USA - 28 September 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration
Released : September 19, 2017 07:00 RNS Number : 0903R MaxCyte, Inc. 19 September 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Results for the Six Months ended 30 June 2017 Maryland, USA - 19 September 2017 - MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the
Released : August 25, 2017 07:00 RNS Number : 9391O MaxCyte, Inc. 25 August 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Notice of Half Year Results Maryland, USA - 25 August 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company driving the acceleration of the discovery,
Released : July 20, 2017 18:02 RNS Number : 6906L MaxCyte, Inc. 20 July 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Maryland, USA - 20 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery,
Released : July 12, 2017 07:00 RNS Number : 7813K MaxCyte, Inc. 12 July 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update Maryland, USA - 12 July 2017: MaxCyte (LSE: MXCT, MXCR), a US-based global company dedicated to driving the acceleration of the discovery, development,
Released : June 06, 2017 07:00 RNS Number : 2054H MaxCyte, Inc. 06 June 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Cooperative Research and Development Agreement MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease
Released : May 31, 2017 16:30 RNS Number : 7231G MaxCyte, Inc. 31 May 2017 MaxCyte, Inc. ("MaxCyte" or the "Company") Total Voting Rights Maryland, USA -31 May 2017: MaxCyte (LSE: MXCT, MXCR) announces that, following an exercise of options, 22,435 new shares of common stock of $0.01